Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.50 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.50 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.41 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 3/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14273456 | 1.00 | MAP3K7 (0.50) | MAP3K7TAB1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL4777410 | 1.00 | MAP3K7 (0.50) | MAP3K7TAB1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL4781768 | 0.90 | MAP3K7 (0.59) | MAP3K7TAB1HSD17B1HSD17B2MAPT | |
| SCHEMBL4978768 | 0.89 | MAP3K7 (0.54) | MAP3K7TAB1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL4978774 | 0.89 | MAP3K7 (0.54) | MAP3K7TAB1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL14273455 | 0.88 | MAP3K7 (0.50) | MAP3K7TAB1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL4781798 | 0.88 | MAP3K7 (0.50) | MAP3K7TAB1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL4781796 | 0.88 | MAP3K7 (0.50) | MAP3K7TAB1CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL4978547 | 0.77 | MAP3K7 (0.64) | MAP3K7TAB1 | |
| SCHEMBL4838997 | 0.77 | MAP3K7 (0.52) | MAP3K7TAB1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | claimed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | claimed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | TUBB1, TUBA1C, TUBB3 | MAP3K7 1090/4885TAB1 981/4885CDYL2 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.